臺北醫學大學 |
2008-02 |
Cetia® / 暢寧®錠
|
藥劑部 |
臺北醫學大學 |
2010-02 |
Cetirizine® / 勝克敏®內服水劑
|
藥劑部 |
高雄醫學大學 |
2006 |
CETP基因多型性和台灣第2型糖尿病患者冠心症之關聯性
|
謝明家;辛世杰;蕭政岳;田凱仁;許世傑;辛錫璋 |
東海大學 |
2009 |
Cetrarioid lichen genera and species in NE China
|
Lai, M.-J., Chen, X.-L., Qian, Z.-G., Xu, L., Anti, T. |
臺大學術典藏 |
2021-09-09T02:26:28Z |
Cette belle viande: Cézanne's bathers of the Impressionist years, 1872-1880
|
CHIAO-MEI LIU |
臺大學術典藏 |
2020-03-05T06:28:37Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.;Lin Y.-L.;Jau-Yu Liau;Tsai J.-H.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Tseng L.-H.;Lin L.-I.;Chang Y.-L.;Cheng A.-L.;Yeh K.-H.; Liang Y.-H.; Lin Y.-L.; JAU-YU LIAU; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; Cheng A.-L.; Yeh K.-H. |
國立臺灣大學 |
2015 |
Cetuximab Might Be Detrimental to Metastatic Colorectal Cancer Patients with KRAS Codon 12 Mutations
|
Liang, Yi-Hsin; Lin, Yu-Lin; Liau, Jau-Yu; Tsai, Jia-Huei; Liang, Jin-Tung; Lin, Been-Ren; Hung, Ji-Shiang; Tseng, Li-Hui; Lin, Liang-In; Chang, Yih-Leong; Cheng, Ann-Lii; Yeh, Kun-Huei; 梁逸歆; 林亮音; 曾麗慧; 張逸良; 林育麟; 鄭安理; 葉坤輝; 蔡佳惠; 洪基翔; 林本仁; 廖肇裕; 梁金銅 |
臺大學術典藏 |
2018-09-10T15:21:53Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang, Y.-H. and Lin, Y.-L. and Liau, J.-Y. and Tsai, J.-H. and Liang, J.-T. and Lin, B.-R. and Hung, J.-S. and Tseng, L.-H. and Lin, L.-I. and Chang, Y.-L. and Cheng, A.-L. and Yeh, K.-H.; YIH-LEONG CHANG |
臺大學術典藏 |
2018-09-10T15:23:10Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang, Y.-H. and Lin, Y.-L. and Liau, J.-Y. and Tsai, J.-H. and Liang, J.-T. and Lin, B.-R. and Hung, J.-S. and Tseng, L.-H. and Lin, L.-I. and Chang, Y.-L. and Cheng, A.-L. and Yeh, K.-H.; Jin-Tung Liang |
臺大學術典藏 |
2018-09-10T15:23:29Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
JAU-YU LIAU; Liang, Y.-H. and Lin, Y.-L. and Liau, J.-Y. and Tsai, J.-H. and Liang, J.-T. and Lin, B.-R. and Hung, J.-S. and Tseng, L.-H. and Lin, L.-I. and Chang, Y.-L. and Cheng, A.-L. and Yeh, K.-H. |
臺大學術典藏 |
2018-09-10T15:25:12Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang, Y.-H. and Lin, Y.-L. and Liau, J.-Y. and Tsai, J.-H. and Liang, J.-T. and Lin, B.-R. and Hung, J.-S. and Tseng, L.-H. and Lin, L.-I. and Chang, Y.-L. and Cheng, A.-L. and Yeh, K.-H.; Ji-Shiang Hung |
臺大學術典藏 |
2020-02-25T05:15:25Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; JI-SHIANG HUNG; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; Cheng A.-L.; Yeh K.-H. |
臺大學術典藏 |
2020-03-07T06:56:23Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.;Lin Y.-L.;Liau J.-Y.;Tsai J.-H.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Tseng L.-H.;Lin L.-I.;Yih-Leong Chang;Cheng A.-L.;Yeh K.-H.; Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; YIH-LEONG CHANG; Cheng A.-L.; Yeh K.-H. |
臺大學術典藏 |
2020-06-16T07:53:31Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.;Lin Y.-L.;Liau J.-Y.;Tsai J.-H.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Tseng L.-H.;Liang-In Lin;Chang Y.-L.;Cheng A.-L.;Yeh K.-H.; Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; LIANG-IN LIN; Chang Y.-L.; Cheng A.-L.; Yeh K.-H. |
臺大學術典藏 |
2020-03-05T07:31:46Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.;Lin Y.-L.;Liau J.-Y.;Jia-Huei Tsai;Liang J.-T.;Lin B.-R.;Hung J.-S.;Tseng L.-H.;Lin L.-I.;Chang Y.-L.;Cheng A.-L.;Yeh K.-H.; Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Yeh K.-H.; Cheng A.-L.; Chang Y.-L.; Lin L.-I.; Tseng L.-H.; JIA-HUEI TSAI; Liang J.-T.; Lin B.-R.; Hung J.-S. |
臺大學術典藏 |
2020-03-06T05:26:12Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; YIH-LEONG CHANG; Cheng A.-L.; Yeh K.-H. |
臺大學術典藏 |
2021-05-03T02:20:55Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.;Lin Y.-L.;Liau J.-Y.;Tsai J.-H.;Jin-Tung Liang;Lin B.-R.;Hung J.-S.;Tseng L.-H.;Lin L.-I.;Chang Y.-L.;Cheng A.-L.;Yeh K.-H.; Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; JIN-TUNG LIANG; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; Cheng A.-L.; Yeh K.-H. |
臺大學術典藏 |
2021-05-07T02:46:37Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
YI-HSIN LIANG; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; Cheng A.-L.; Yeh K.-H. |
臺大學術典藏 |
2021-08-31T06:29:50Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; ANN-LII CHENG; Yeh K.-H. |
臺大學術典藏 |
2022-03-10T07:58:41Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; LI-HUI TSENG; Lin L.-I.; Chang Y.-L.; Cheng A.-L.; Yeh K.-H. |
臺大學術典藏 |
2021-01-28T01:06:29Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.;Lin Y.-L.;Liau J.-Y.;Tsai J.-H.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Tseng L.-H.;Lin L.-I.;Chang Y.-L.;Cheng A.-L.;Kun-Huei Yeh; Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; Cheng A.-L.; KUN-HUEI YEH |
臺北醫學大學 |
2006 |
Cetuximab plus chemotherapy as salvage treatment for advanced colorectal cancer in Taiwanese: Experiences in Taipei Medical University Hospital
|
戴承正; Cheng-Jeng Tai; Chih-Hsiung Wu; Ching-Shyang Chen; Min-Ter Huang; Jeng-Feng Chiou; Chen-Jei Tai |
臺北醫學大學 |
2006 |
Cetuximab plus chemotherapy as salvage treatment for advanced colorectal cancer in Taiwanese:Experiences in Taipei Medical University Hospital
|
吳志雄; 黃銘德; Tai CJ; Wu CH; Chen CS; Huang MT; Chiou JF; Tai CJ; |
臺北醫學大學 |
2006 |
Cetuximab plus chemotherapy as salvage treatment for advanced colorectal cancer in Taiwanese;Experiences in Taipei Medical University Hospital
|
邱仲峰; C; J; Tai; C; H; Wu; C; S; Chen; M; T; Huang; J; F; Chiou; C; J; Tai |
高雄醫學大學 |
2007 |
Cetuximab合併化學治療於轉移性結直腸癌:表皮生長因子受器表現的角色
|
王照元 |